Robert Jech

Robert Jech

Auto-generated profile, based on publicly available information

Robert Jech

Dept. of Neurology and Center of Clinical Neuroscience, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Katerinska 30, Praha 2, Czech Republic

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1997 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
TPTomáš Paus
Tomáš Paus
RJRobert Jech
Robert Jech
CTChristopher J. Thompson
Christopher J. Thompson
RCRoch Comeau
Roch Comeau
TPTerry Peters
Terry Peters
AEAlan C. Evans
Alan C. Evans
We describe a new technique permitting the mapping of neural connections in the living human brain. The method combines two well established tools of brain research: transcranial magnetic stimulation (TMS) and positron emission tomography (PET). We use TMS to stimulate directly a selected cortical area while simultaneously measuring changes in brain activity, indexed by cerebral blood flow (CBF), with PET. The exact location of the stimulation site is achieved by means of frameless stereotaxy. In the first study using this technique, we found significant positive correlations between CBF and the number of TMS pulse trains at the stimulation site, namely the left frontal eye field (FEF) and, most importantly, in the visual cortex of the superior parietal and medial parieto-occipital regions. The pattern of these distal effects was consistent with the known anatomic connectivity of the monkey FEF. We suggest that the combined TMS/PET technique offers an objective tool for assessing the state of functional connectivity without requiring the subject to engage in any specific behavior.

1 December 2017 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
Angelo AntoniniAngelo Antonini
Angelo Antonini
WPWerner Poewe
Werner Poewe
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
RJRobert Jech
Robert Jech
BPBarbara Pickut
Barbara Pickut
MZMichel Van Zandijcke
Michel Van Zandijcke
This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care. Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients with ≤12 months of pre-treatment with LCIG (40% of patients). Hours of "On" and "Off" time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale part IV items 32 and 39. Overall, 375 patients were enrolled by 75 movement disorder centers in 18 countries and 258 patients completed the registry. At 24 months LCIG treatment led to significant reductions from baseline in "Off" time (hours/day) (mean ± SD = -4.1 ± 3.5, P < 0.001), "On" time with dyskinesia (hours/day) (-1.1 ± 4.8, P = 0.006), Non-Motor Symptom Scale total (-16.7 ± 43.2, P < 0.001) and individual domains scores, and Parkinson's Disease Questionnaire-8 item total score (-7.1 ± 21.0, P < 0.001). Adverse events deemed to have a possible/probable causal relationship to treatment drug/device were reported in 194 (54%) patients; the most frequently reported were decreased weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device issues (4.8%), and polyneuropathy (4.5%). LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.

1 October 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
Jean-Michel GraciesJean-Michel Gracies
Jean-Michel Gracies
ABAllison Brashear
Allison Brashear
RJRobert Jech
Robert Jech
PMPeter McAllister
Peter McAllister
MBMarta Banach
Marta Banach
PPPhilippe Picaut
Philippe Picaut

1 February 1998 in Journal of Neurophysiology
Verified
Journal Article
Open access
PDF file
TPTomáš Paus
Tomáš Paus
RJRobert Jech
Robert Jech
CTChristopher J. Thompson
Christopher J. Thompson
RCRoch Comeau
Roch Comeau
TPTerry Peters
Terry Peters
AEAlan C. Evans
Alan C. Evans
Paus, Tomáš, Robert Jech, Christopher J. Thompson, Roch Comeau, Terry Peters, and Alan C. Evans. Dose-dependent reduction of cerebral blood flow during rapid-rate transcranial magnetic stimulation of the human sensorimotor cortex. J. Neurophysiol. 79: 1102–1107, 1998. Rapid-rate transcranial magnetic stimulation (rTMS) was used to stimulate the primary sensorimotor cortex in six healthy volunteers while regional changes in cerebral blood flow (CBF) were simultaneously measured by means of positron emission tomography. A figure-eight TMS coil (Cadwell Corticoil) was positioned, using frameless stereotaxy, over the probabilistic location of the left primary sensorimotor cortex, and a series of brief 10-Hz trains of TMS was delivered at subthreshold intensity during each of six 60-s scans. The scans differed in the number of trains delivered, namely 5, 10, 15, 20, 25, and 30 trains/scan, respectively. In the left primary sensorimotor cortex, CBF covaried significantly and negatively with the number of stimulus trains. These CBF decreases may reflect TMS–induced activation of local inhibitory mechanisms known to play a role in TMS–related phenomena, such as the electromyographic silent period.

5 March 2010 in Brain
Verified
Journal Article
Open access
PDF file
LTL. Timmermann
L. Timmermann
KPK. A. M. Pauls
K. A. M. Pauls
KWK. Wieland
K. Wieland
RJR. Jech
R. Jech
GKG. Kurlemann
G. Kurlemann
Selçuk PekerSelçuk Peker
Selçuk Peker
Neurodegeneration with brain iron accumulation encompasses a heterogeneous group of rare neurodegenerative disorders that are characterized by iron accumulation in the brain. Severe generalized dystonia is frequently a prominent symptom and can be very disabling, causing gait impairment, difficulty with speech and swallowing, pain and respiratory distress. Several case reports and one case series have been published concerning therapeutic outcome of pallidal deep brain stimulation in dystonia caused by neurodegeneration with brain iron degeneration, reporting mostly favourable outcomes. However, with case studies, there may be a reporting bias towards favourable outcome. Thus, we undertook this multi-centre retrospective study to gather worldwide experiences with bilateral pallidal deep brain stimulation in patients with neurodegeneration with brain iron accumulation. A total of 16 centres contributed 23 patients with confirmed neurodegeneration with brain iron accumulation and bilateral pallidal deep brain stimulation. Patient details including gender, age at onset, age at operation, genetic status, magnetic resonance imaging status, history and clinical findings were requested. Data on severity of dystonia (Burke Fahn Marsden Dystonia Rating Scale—Motor Scale, Barry Albright Dystonia Scale), disability (Burke Fahn Marsden Dystonia Rating Scale—Disability Scale), quality of life (subjective global rating from 1 to 10 obtained retrospectively from patient and caregiver) as well as data on supportive therapy, concurrent pharmacotherapy, stimulation settings, adverse events and side effects were collected. Data were collected once preoperatively and at 2–6 and 9–15 months postoperatively. The primary outcome measure was change in severity of dystonia. The mean improvement in severity of dystonia was 28.5% at 2–6 months and 25.7% at 9–15 months. At 9–15 months postoperatively, 66.7% of patients showed an improvement of 20% or more in severity of dystonia, and 31.3% showed an improvement of 20% or more in disability. Global quality of life ratings showed a median improvement of 83.3% at 9–15 months. Severity of dystonia preoperatively and disease duration predicted improvement in severity of dystonia at 2–6 months; this failed to reach significance at 9–15 months. The study confirms that dystonia in neurodegeneration with brain iron accumulation improves with bilateral pallidal deep brain stimulation, although this improvement is not as great as the benefit reported in patients with primary generalized dystonias or some other secondary dystonias. The patients with more severe dystonia seem to benefit more. A well-controlled, multi-centre prospective study is necessary to enable evidence-based therapeutic decisions and better predict therapeutic outcomes.

9 November 2001 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
RJRobert Jech
Robert Jech
DUDušan Urgošík
Dušan Urgošík
JTJaroslav Tintěra
Jaroslav Tintěra
ANAntonín Nebuželský
Antonín Nebuželský
JKJan Krásenský
Jan Krásenský
EREvžen Růžička
Evžen Růžička